OncoMatch/Clinical Trials/NCT05440149
The Postoperative Radiotherapy in N1 Breast Cancer Patients
Is NCT05440149 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for radiotherapy.
This study is a multicenter, randomized, phase 3 clinical trial in patients with breast cancer, randomizing radiotherapy group (postmastectomy radiation therapy (PMRT)/whole breast irradiation plus regional radiotherapy (WBI+regional RT) versus and no PMRT/WBI alone group. This is a non-inferiority study aiming that there is no significant difference in the 7-year disease-free survival rate between the two groups.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: ESR1 hormone receptor positive
Patients undergoing or planning to undergo hormone therapy in the case of hormone receptor positive
Allowed: HER2 (ERBB2) positive
Patients who have received or are expected to undergo targeted therapy in the case of human epidermal growth factor receptor(HER)-2 positive
Disease stage
Required: Stage PN1
stage pN1 after surgery on histopathologic examination; Patients with stage T4 [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: neoadjuvant chemotherapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify